SCHEMBL98351

SCHEMBL98351

[CH2]c1ccc(OCCCC)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.57
NR5A1 Q13285 1/20 0.55
CYP3A4 P08684 3/20 0.53
CYP2D6 P10635 3/20 0.53
TSHR P16473 2/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CYP1A2 P05177 3/20 0.49
CYP19A1 P11511 3/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2C19 P33261 3/20 0.49
GAA P10253 1/20 0.48
RAB9A P51151 1/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1119457 0.96 NR5A1 (0.62) LTA4HNR5A1CYP3A4CYP2D6TSHR
SCHEMBL15106754 0.94 NR5A1 (0.66) LTA4HNR5A1TSHRGAARAB9A
SCHEMBL2093730 0.94 NR5A1 (0.66) LTA4HNR5A1TSHRGAARAB9A
SCHEMBL6745183 0.94 NR5A1 (0.66) LTA4HNR5A1TSHRGAARAB9A
SCHEMBL11321046 0.94 NR5A1 (0.66) LTA4HNR5A1TSHRGAARAB9A
SCHEMBL10878033 0.94 NR5A1 (0.66) LTA4HNR5A1TSHRGAARAB9A
SCHEMBL2094301 0.94 NR5A1 (0.66) LTA4HNR5A1TSHRGAARAB9A
SCHEMBL3092648 0.94 NR5A1 (0.66) LTA4HNR5A1TSHRGAARAB9A
SCHEMBL1119584 0.94 NR5A1 (0.66) LTA4HNR5A1TSHRGAARAB9A
SCHEMBL377178 0.94 NR5A1 (0.66) LTA4HNR5A1TSHRGAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-11-02 US claimed
EP-4146623-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2023-03-15 EP claimed
CN-115803025-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2023-03-14 CN claimed
WO-2021224864-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2021-11-11 WO claimed
EP-2426106-B1 Piperidine and Piperazine derivatives for the treatment of tumours MERCK PATENT GMBH (DE) 2013-07-31 EP claimed
WO-2006103119-A2 TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-05 WO claimed
US-20050009912-A1 Prodrugs of excitatory amino acids ELI LILLY AND COMPANY 2005-01-13 US claimed
EP-1458671-A1 PRODRUGS OF EXCITATORY AMINO ACIDS ELI LILLY AND COMPANY (US) 2004-09-22 EP claimed
US-20040138304-A1 Prodrugs of excitatory amino acids ELI LILLY AND COMPANY 2004-07-15 US claimed
US-20040063760-A1 Sodium channel modulatiors THERAVANCE BIOPHARMA R&D IP, LLC 2004-04-01 US claimed
CN-1058260-C Na -2 -(4 -nitrophenulsulfonyl) ethoxycarbonyl -amino acids HYUNDAI PHARM IND CO LTD (KR) 2000-11-08 CN claimed
EP-1041074-A1 Light-sensitive 4-cyanocoumarin derivatives KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2000-10-04 EP claimed
WO-2000043415-A1 COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2000-07-27 WO claimed
EP-0998946-A1 Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2000-05-10 EP claimed
WO-2000009169-A1 NON-PORPHYRIN COMPOUND FOR USE AS A DIAGNOSTICUM AND/OR PHARMACEUTICAL K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2000-02-24 WO claimed
CN-1173865-A Na-2- (4-nitrobenzenesulfonyl) ethoxycarbonyl-amino acids HYUNDAI PHARM IND CO LTD (KR) 1998-02-18 CN claimed
US-4591376-A PLANT GROWTH REGULATORS SCHERING AKTIENGESELLSCHAFT (DE) 1986-05-27 US claimed
EP-0126234-A2 1,2,3-Thiadiazol-3-in-5-ylidene ureas, their preparation and compositions as plant-growth regulators and defoliants SCHERING AKTIENGESELLSCHAFT (DE) 1984-11-28 EP claimed
US-4029690-A WITH 2,5-DIMETHYL-2,4-HEXADIENE AND AN ALKYL DIAZOACETATE WITH A COPPER COMPLEX CATALYST SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-06-14 US claimed
US-4029683-A WITH A SCHIFF BASE, CHRYSANTHEMATE SYNTHESIS CATALYST SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-06-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA LTA4H 350/4885NR5A1 4858/4885CYP3A4 2683/4885
US-20040063760-A1 Sodium channel modulatiors SCN1A, SCN2A, SCN1B LTA4H 454/4885NR5A1 3444/4885CYP3A4 4631/4885
US-20050009912-A1 Prodrugs of excitatory amino acids SLC1A2, SLC1A3, SLC1A1 LTA4H 3098/4885NR5A1 1621/4885CYP3A4 971/4885
US-20040138304-A1 Prodrugs of excitatory amino acids SLC1A2, SLC1A1, SLC1A3 LTA4H 1849/4885NR5A1 2891/4885CYP3A4 861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.